Exhaled Nitric Oxide Today s Asthma Biomarker. Richard F. Lavi, MD FAAAAI FAAP
|
|
- Brent Cole
- 6 years ago
- Views:
Transcription
1 Exhaled Nitric Oxide Today s Asthma Biomarker Richard F. Lavi, MD FAAAAI FAAP
2 Objectives Describe exhaled nitric oxide physiology and pathophysiology Review the current literature regarding exhaled nitric oxide testing Explore potential applications of exhaled nitric oxide measurement in clinical care
3 Disclosure Member of Aerocrine Speakers Bureau. ENO medical device manufacturer. No other relevant financial disclosures.
4 Biomarker? A characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Biomarkers Definitions Working Group. Clin Pharmacol Ther. 2001;69(3):89-95.
5 The Search for Biomarkers Asthma: complex, heterogeneous disease Endotypes are key Allergic and eosinophilic asthma endotypes are well-recognized How do we endotype asthmatics to provide the most appropriate and effective tailored therapies? Here, try this. This will be effective. Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske RF Jr, Wardlaw AJ, Wenzel SE, Greenberger PA. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol Feb;127(2):
6 Biomarkers In Asthma Reduce risk of misdiagnosis Better define asthma endotype Evaluate response to therapy Improve disease management
7 Inflammation In Asthma From: Durrant & Metzger (2010) Immunol Invest 39:
8 Asthma Biomarker Candidates Total eosinophil count Sputum eosinophils Difficult to collect clinically Urinary leukotrienes Airway imaging Dynamic CT Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, Hunt JF, Kita H, Liu AH, Panettieri RA Jr, Schleimer RP, Minnicozzi M. Asthma outcomes: biomarkers. J Allergy Clin Immunol Mar;129(3 Suppl):S9-23.
9 When in Rome
10 Airway Inflammation Markers Bronchoscopy Bronchial wash BAL Biopsy AHR Sputum investigation Breath condensates NO in exhaled air
11 Physiology of ENO HEALTHY NO Soluble mediator inos STAT-1 Corticosteroidresistant mechanism IFN-γ (homeostatic, source unknown) Kjell Alving & Andrei Malinovschi (2010). Eur Respir Monograph 49: 1-31.
12 Pathophysiology in Allergic Asthma ASTHMA NO NO NO Air pollution (oxidative stress) Allergen exposure inos AP-1 inos STAT-6 Mucus, AHR Corticosteroidsensitive mechanism IL-4/ IL-13 (Th2 cells, mast cells, eosinophils) Kjell Alving & Andrei Malinovschi (2010). Eur Respir Monograph 49: 1-31.
13 inos in the Lower Airways Control Asthma (- steroid) Asthma (+ steroid) Redington et al. (2001) Thorax 56: 351-7
14 ENO Standardization ERS 1997 ATS 1999 ERS 2001 ATS/ERS 2005
15 THE 2011 AMERICAN THORACIC SOCIETY GUIDELINES DEFINED HOW ENO SHOULD BE USED IN CLINICAL PRACTICE Diagnosis Treatment Monitoring Adherence Dweik et al. Am J Respir Crit Care Med. 2011;184(5): EMD/000585/00
16 ENO TESTING Diagnosis Diagnose eosinophilic airway inflammation Support asthma diagnosis when objective evidence is needed Assist in assessing etiology of respiratory symptoms Help identify eosinophilic asthma phenotype Dweik et al. Am J Respir Crit Care Med. 2011;184(5):
17 ENO TESTING IN THE INITIAL ASSESSMENT OF ASTHMA Parameter* Sensitivity, % Specificity, % PPV, % NPV, % Peak flow improvement with steroid >15% FEV 1 improvement with steroid >15% FEV 1 <80% predicted FEV 1 /FVC <70% Sputum eosinophils >3% FeNO >20 ppb Bronchodilator reversibility and AHR used to establish asthma diagnosis in study Both FeNO and sputum eosinophils had significantly higher accuracy than lung function tests FeNO testing provides added advantage of being noninvasive and easy to perform FEV 1, forced expiratory volume at 1 second; FVC, forced vital capacity; NPV, negative predictive value; Ppb, parts per billion; PPV, positive predictive value. *47 patients with symptoms suggestive of asthma, with 17 subsequently diagnosed with asthma. Smith et al. Am J Respir Crit Care Med. 2004;169(4): EMD/000585/00
18 ENO SIGNIFICANTLY P= ELEVATED IN ASTHMA FeNO, ppb Allergic asthma n=56 P= Nonallergic asthma n=45 P= Healthy volunteers n=39 FeNO levels significantly increased in both asthma groups FeNO levels significantly higher in patients with allergic asthma versus patients with nonallergic asthma Figure from Zietkowski et al. With permission. Zietkowski et al. J Investig Allergol Clin Immunol. 2006;16(4):
19 ENO LEVELS SIGNIFICANTLY HIGHER IN ASTHMA COMPARED WITH COPD FeNO, ppb 40 P< ppb considered 11 cut point 0 COPD (n=27) Asthma (n=19) Figure reprinted from Fabbri et al with permission of the American Thoracic Society. Copyright 2011 American Thoracic Society. Patients aged >50 yrs with postbronchodilator FEV 1 /FVC <70% and history of asthma or chronic obstructive pulmonary disease (COPD). Horizontal bar represents median value. Fabbri et al. Am J Respir Crit Care Med. 2003;167(3):
20 ENO TESTING Treatment Determine likelihood of individual patient response to antiinflammatory agents, including ICS Guide changes in dosing of anti-inflammatory medications Step-down or step-up dosing or discontinuation of anti-inflammatory medications Dweik et al. Am J Respir Crit Care Med. 2011;184(5):
21 "FeNO has been shown to predict the likelihood of steroid responsiveness more consistently than spirometry, bronchodilator response, peak flow variation, or AHR to methacholine." Dweik et al. Am J Respir Crit Care Med. 2011;184(5):
22 ENO MONITORING VERSUS CONVENTIONAL MANAGEMENT FOR ICS DOSE TITRATION 40 Control group (n=48) Exacerbations, n P=0.27 ENO group (n=46) Months 46% reduction 0.5 and 0.9 exacerbations per patient per year in ENO and control groups, respectively Did not meet superiority statistical threshold of 60% reduction Figure from Smith et al. With permission from Massachusetts Medical Society. Smith et al. N Engl J Med. 2005;352(21): EMD/000585/00
23 DOSE DISTRIBUTION OF INHALED FLUTICASONE AT STUDY COMPLETION ENO group (n=46) Control group (n=48) P=0.008 for distribution Patients, % Fluticasone, µg/d Figure from Smith et al. With permission from Massachusetts Medical Society. Smith et al. N Engl J Med. 2005;352(21): EMD/000585/00
24 ENO-GUIDED ASTHMA MANAGEMENT DURING PREGNANCY 75 Control group (n=109) ENO group (n=111) 900 Control group (n=109) ENO group (n=111) Exacerbations, n Mean ICS dose, µg/d P= Time, weeks 25% females in ENO group had an exacerbation versus 41% of patients in control group (P=0.011) NNT= 6; for every 6 receiving treatment adjustment by ENO-based algorithm, 1 was prevented from having an exacerbation Significant reduction in neonatal hospitalizations in ENO group (8%) vs control group (17%; P=0.046) Figures reprinted from The Lancet, 378, Powell et al, Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial, , Copyright 2011, with permission from Elsevier. NNT, number needed to treat. Powell et al. Lancet. 2011;378(9795): Visit 24 EMD/000585/00
25 AN INVESTIGATION OF ASTHMA CARE BEST PRACTICE IN A COMMUNITY HEALTH CENTER Journal of Health Care for the Poor and Underserved. 2012;23: EMD/000585/00
26 UHP ASTHMA PREVALENCE RATES 1. Lester et al. J Health Care Poor Underserved. 2012;23: Akinbami LJ et al. Asthma Prevalence, Health Care Use, and Mortality: United States, January 12, DHHS Publication No. (PHS) National Health Statistics Reports No Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Data &qkey=4416&state=All. Accessed August 15, EMD/000585/00
27 THE UHP PLAN Key elements of the plan Screen for symptoms, ER visits, hospitalizations, and intubations ACT Review medication use Develop an asthma action plan Set self-management goals ENO to help identify exacerbation risk and adherence to controller medications (ages 6 and older) Biannual spirometry Lester et al. J Health Care Poor Underserved. 2012;23: EMD/000585/00
28 ER/URGENT CARE VISITS PRE- AND POST- PROGRAM IMPLEMENTATION Lester et al. J Health Care Poor Underserved. 2012;23: EMD/000585/00
29 UHP COST COMPARISON Lester et al. J Health Care Poor Underserved. 2012;23: EMD/000585/00
30 ASTHMA MANAGEMENT USING ENO AND GUIDELINE- BASED TREATMENT FOR INNER-CITY ADOLESCENTS Control group (n=270) ENO monitoring group (n=276) 40 Maximum days with symptoms, n Run-in Mean ENO, ppb Run-in Week Week Figures reprinted from The Lancet, 372, Szefler et al, Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial, , Copyright 2008, with permission from Elsevier. Szefler et al. Lancet. 2008;372(9643): EMD/000585/00
31 STUDY CONSIDERATIONS Significant (P<0.0001) differences in 3-week run-in period versus pre-study levels Mean ICS dose of 219 µg/d 12.9-ppb in mean ENO levels ( ppb) 3.4-day in mean maximum symptomatic days (from days) 3.0-point in ACT score (18.2 [poor] 21.2 [good control]) 3.3% in FEV 1 % predicted (92% 95%) Protocol issues Patients excluded if <25% adherence during run-in period If symptoms present, protocol mandated ICS dose increase even if low ENO levels; protocol did not permit ICS dose decrease if ENO levels low Primary endpoint, number of days with asthma symptoms, not reflective of ENO measurement utility - ENO levels poorly correlated with symptoms Fewer patients in ENO group (32%) required 1 prednisone course versus control (42%; P=0.01). Szefler et al. Lancet. 2008;372(9643): EMD/000585/00
32 ENO TESTING: MONITORING AND ADHERENCE Monitoring and adherence Establish baseline ENO level during clinical stability for subsequent monitoring of chronic, persistent asthma Monitor airway inflammation levels in patients with asthma Account for persistent and/or high allergen exposure as a factor associated with elevated ENO levels Assist in evaluation of adherence to ICS treatment Assess whether airway inflammation is contributing to poor asthma control Dweik et al. Am J Respir Crit Care Med. 2011;184(5): EMD/000585/00
33 ENO INTERPRETATION: PATIENTS WITH SUSPECTED ASTHMA LOW FeNO level <25 ppb in adults <20 ppb in children Eosinophilic inflammation less likely INTERMEDIATE/ INCREASING FeNO level* ppb in adults ppb in children HIGH FeNO level >50 ppb in adults >35 ppb in children Eosinophilic inflammation likely Symptomatic patients unlikely to benefit from trial of ICS therapy; consider other possible etiologies Symptomatic patients likely to benefit from trial of ICS therapy; investigate allergen exposure Cautious interpretation; based on clinical judgment, consider initiating trial of ICS therapy and monitor change in FeNO levels *Increasing defined as >40% increase from previous stable FeNO level. Chronic cough and/or wheeze and/or shortness of breath for >6 weeks. For example, rhinosinusitis, bronchiectasis, primary ciliary dyskinesia, anxiety-hyperventilation, cardiac disease, GERD, or vocal cord dysfunction. Dweik et al. Am J Respir Crit Care Med. 2011;184(5): EMD/000585/00
34 SEVERAL FACTORS MAY INCREASE OR DECREASE ENO LEVELS Airway infection 1 Allergic rhinitis 2 Nitrate-rich diet 3 Bronchodilator 4 - Spirometric maneuvers 5 Exercise 6 Alcohol consumption 7 Bronchoconstriction 6, 8 Ciliary dyskinesia 9 Pulmonary hypertension 10 Cystic fibrosis 9 Smoking 11 ICS therapy 11,12 1. Sanders et al. J Allergy Clin Immunol. 2004;113(4): Henriksen et al. Eur Respir J. 1999;13(2): Olin et al. Respir Med. 2001;95(2): Papi et al. Am J Respir Crit Care Med. 2000;162(5): Silkoff et al. Am J Respir Crit Care Med. 1999;159: Terada et al. Am J Respir Crit Care Med. 2001;164: Yates et al. Eur Respir J. 1996;9(6): Piacentini et al. Thorax. 2002;57: Narang et al. Thorax. 2002;57(7): Kaneko et al. Am J Respir Crit Care Med. 1998;158(3): Verleden et al. Chest. 1999;116(1): Silkoff et al. J Allergy Clin Immunol. 2004;114(5):
35 INTERPRETATION OF ENO MEASUREMENTS Use cut points rather than reference values Account for age as a factor in children <12 years old Clinical context in which ENO is obtained should be taken into account and reported* When monitoring patients, clinically significant increase determined as >20% change for levels >50 ppb >10-ppb change for levels <50 ppb Decrease of >20% in an elevated ENO level, which often occurs 2 to 6 weeks after initiation of anti-inflammatory therapy, supports that treatment was successful for reduction of inflammation *Includes date, time of day, age, sex, ethnicity, height, weight, smoking status, reasons for test, prior diagnosis if known, whether patient was using ICS or oral steroids at time of testing, and number of measurements made. Dweik et al. Am J Respir Crit Care Med. 2011;184(5):
36 Pearls? ENO as a personal best. ENO is a test of steroid responsive airway inflammation. ENO to test for and/or monitor successful steroid discontinuation? ENO to predict exacerbation. ENO to monitor adherence and possible ongoing allergen exposure.
37 4-STEP PROCEDURE 1. Empty lungs 2. Inhale deeply through disposable filter 3. Exhale through disposable filter 4. View results on screen
38 Case Study: Lauren Patient characteristics Female, 21 years old Reason for visit Increasingly severe asthma Patient history Asthma, atopic dermatitis, allergic rhinitis since early childhood Hospitalized >10 times in her lifetime; 2 times this year, including ICU visit 2 weeks ago Current medications High-dose ICS/LABA combination, LTRA once daily, SABA prn Intranasal steroids once daily Finished oral corticosteroid taper 3 days ago Present illness Symptoms of cough, wheeze, dyspnea requiring SABA 4 to 5 times/week Nighttime awakenings, 1 to 2 times/week Avoids exercise due to increased symptoms Asthma triggers: animal exposure, viral infections, changes in weather, and wind ICU, intensive care unit; LABA, long-acting beta-agonist; LTRA, leukotriene receptor antagonist; prn, as needed; SABA, short-acting beta-agonist.
39 Case Study: Lauren Other information Hospital lab results: total IgE level, 653 ku/l; peripheral eosinophils, 6%; specific IgE positivity for cat, dog, Aspergillus, Alternaria, rye grass, dust mite, ragweed, and elm Assessment Pre-BD Post-BD % Change FVC, % predicted FEV 1, % predicted FEV 1 /FVC, % FeNO, ppb 68 BD, bronchodilator.
40 Lauren: Control Assessment Impairment SABA use Activity limitations Daytime symptoms Nighttime symptoms Lung function FeNO Controlled Not controlled Risk Exacerbations FeNO Controlled Not controlleded
41 Lauren: Follow-up and Plan Plan Continue current medications encouraged improved adherence with all medications Allergen avoidance measures Follow up in 2 weeks Follow-up Reports regular use of medications Symptoms 2 days/week; SABA used 2 times/week; no nighttime awakenings; has not tried exercising Assessment Pre-BD Post-BD % Change FVC, % predicted FEV 1, % predicted FEV 1 /FVC, % FeNO, ppb 134
42 Lauren: Control Assessment 2 Impairment Controlled Not controlled SABA use Activity limitations?? Daytime symptoms Nighttime symptoms Lung function FeNO Risk Exacerbations FeNO Controlled Not controlled
43 Lauren: Plan and Follow-up Plan Due to relatively normal lung function, good adherence, and limited symptom burden, decision made not to change therapy Asked to follow up in 1 to 2 months, sooner if having problems Contacted 5 days later by hospital after admission to ICU for continuous bronchodilator nebulization and IV steroids
44 Current medications Lauren: 2 days Post- Hospitalization Scheduled albuterol 2.5 mg neb every 8 hours Oral prednisone 20 mg twice daily, with tapering over 10 days High-dose ICS/LABA, LTRA, and intranasal steroids Present illness Reports slight ongoing dyspnea, frequent daytime and nighttime cough Continues to restrict activity Reports being scared of her asthma Assessment Pre-BD Post-BD % Change FVC, % predicted FEV 1, % predicted FEV 1 /FVC, % FeNO, ppb 47
45 Lauren: 2 weeks post-hospitalization Current medications Last dose of prednisone 3 days ago (10 mg) Last used SABA 4 days ago Remains on high-dose ICS/LABA, LTRA, and intranasal steroids Present illness Daytime symptoms once in the last week No nighttime awakenings Has been avoiding work due to concern with possible virus exposure Reports good adherence with medications Assessment Pre-BD Post-BD % Change FVC, % predicted FEV 1, % predicted FEV 1 /FVC, % FeNO, ppb 89
46 Lauren: Control Assessment 3 Impairment SABA use Controlled Not controlled Activity limitations?? Daytime symptoms Nighttime symptoms Lung function FeNO Risk Exacerbations FeNO Controlled Not controlled
47 Lauren: Post-hospital Plan Plan Based on significant increase in FeNO (47 to 89 ppb) decision made to add second inhaled steroid to current high-dose ICS/LABA and LTRA Given oral steroids to have on hand in case of any sudden increase in symptoms Omalizumab recommended approval process initiated Follow-up scheduled every 2 weeks
48 Lauren Key Points Spirometry and symptom measures do not provide information about the inflammatory status of the airway Following ENO longitudinally over time can aid the clinician in identifying a patient at risk for exacerbation, even in the absence of symptoms or abnormal lung function Patients with severe asthma and a persistently elevated ENO level are likely to have a high-risk phenotype Ongoing inflammation increases the risk of future exacerbations A significant increase in ENO should prompt adjustment to therapy, assessment of treatment adherence, or evaluation for ongoing allergen exposure
49 Conclusion Differentiate asthma from other conditions Predict loss of control and adherence FeNO levels Identify likelihood of response to ICS therapy Predict asthma relapse Guide and optimize ICS therapy
Clinical Benefits of FeNO Monitoring in Asthma RYAN BURTON, MS, RPFT
Clinical Benefits of FeNO Monitoring in Asthma RYAN BURTON, MS, RPFT Disclosures I am an employee of Circassia Pharmaceuticals. Objectives Nitric Oxide Inflammation in Asthma Phenotyping Personalized Medicine
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationAmanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ
Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationUsing Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
More informationAsthma 2015: Establishing and Maintaining Control
Asthma 2015: Establishing and Maintaining Control Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, APRN, NP-C, AE-C June 16, 2015 Asthma Prevalence Approx. 26
More informationOptimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers?
Disclosures: Optimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers? Stanley Fineman, MD Past-President, American College of Allergy, Asthma & Immunology Adjunct Associate
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More information10801 Sixth St, Rancho Cucamonga, CA Tel (909) Fax (909) Visit our web site at:
for the Diagnosis and Management of Asthma and Other Pulmonary Disorders IEHP Policy: Based on a review of the currently available literature, there is insufficient evidence to support the use of FE NO
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2017?
Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome
More informationImportance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma
Original Article Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma Feng-Jia Chen, Huai Liao, Xin-Yan Huang, Can-Mao Xie Department of Respiratory
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More information(Asthma) Diagnosis, monitoring and chronic asthma management
Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationImproving the Management of Asthma to Improve Patient Adherence and Outcomes
Improving the Management of Asthma to Improve Patient Adherence and Outcomes Robert Sussman, MD Atlantic Health System Overlook Medical Center Asthma Remains a Serious Health Risk in the US Every day in
More informationMeasure breath nitric oxide for airway inflammation with the NObreath FeNO monitor
Measure breath nitric oxide for airway inflammation with the NObreath FeNO monitor British technology Improving asthma management, one breath at a time. www.bedfont.com w on 01622 851122 or email ask@bedfont.com
More informationBiologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationControversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More informationCynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationAsthma Therapy 2017 JOSHUA S. JACOBS, M.D.
Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationTreating the right patient with the right
Asthma Getting it Right. Diagnosis, phenotypes, guidelines Treating the right patient with the right treatment Rama Vancheeswaran, FRCP, MSc Immunology, PhD Royal Free Hospital NHS Trust (Barnet site)
More information7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test)
Definition of Asthma GINA 2010: Chronic inflammatory disorder of the airways Airway hyper-responsiveness Recurrent wheezing, breathlessness, chest tightness, coughing Variable, reversible airflow obstruction
More informationAllergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.
Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Chapter 75: Approach to Infants and Children with Asthma
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationAsthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None
Asthma in Pediatric Patients DanThuy Dao, D.O., FAAP Disclosures None Objectives 1. Discuss the evaluation and management of asthma in a pediatric patient 2. Accurately assess asthma severity and level
More informationCurrent Approaches to Asthma & COPD
10/11/18 Current Approaches to Asthma & COPD Lekshmi Santhosh, M.D. Assistant Professor, Pulm/Critical Care & Hosp Med Primary Care Medicine: Principles & Practice 10.11.2018 Revisiting the Dutch Hypothesis:
More informationASTHMA TREATMENT EFFICACY ASSESSMENT BY FeNO MEASUREMENT
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 ASTHMA TREATMENT EFFICACY ASSESSMENT BY FeNO MEASUREMENT Dana ALEXANDRESCU 1 Abstract: The author of
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationPreschool Asthma What you need to know in 10 minutes
Preschool Asthma What you need to know in 10 minutes Alan Kaplan MD CCFP(EM) FCFP Family Physician Airways Group of Canada Respiratory Medicine section CFPC Faculty/Presenter Disclosure Faculty: Alan Kaplan
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationSomkiat Wongtim Professor of Medicine Division of Respiratory Disease and Critical Care Chulalongkorn University
Somkiat Wongtim Professor of Medicine Division of Respiratory Disease and Critical Care Chulalongkorn University Asthma-related Comorbidities Comorbid conditions of the upper airways Rhinitis and Sinusitis
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: exhaled_nitric_oxide_measurement 2/2009 3/2018 3/2019 3/2018 Description of Procedure or Service Asthma is
More informationPersonalized medicine in childhood asthma. Dr Mariëlle Pijnenburg, Erasmus MC Sophia, Rotterdam, NL
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationAsthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
More informationDiagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which
More informationMEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association
MEDICAL POLICY SUBJECT: MEASUREMENT OF EXHALED MARKERS OF AIRWAY INFLAMMATION IN PATIENTS WITH ASTHMA POLICY NUMBER: 2.01.41 CATEGORY: Technology Assessment EFFECTIVE DATE: 04/15/04 REVISED DATE: 02/17/05,
More informationDifficult Asthma Assessment: A systematic approach
Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia
More informationExhaled Nitric Oxide and Exhaled Breath Condensate in the Management of Respiratory Disorders
Medical Coverage Policy Effective Date... 2/15/2018 Next Review Date... 2/15/2019 Coverage Policy Number... 0439 Exhaled Nitric Oxide and Exhaled Breath Condensate in the Management of Respiratory Disorders
More informationAsthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management
Asthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management Eugene R. Bleecker, MD Professor and Director, Center for Genomics & Personalized Medicine Research Professor, Translational
More informationAsthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness
Asthma - Chronic Definition of asthma Chronic inflammatory disease of the airways 3 components: o Reversible and variable airflow obstruction o Airway hyper-responsiveness to stimuli o Inflammation of
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationWhich asthma patient has allergic airway inflammation?
Which asthma patient has allergic airway inflammation? C o n t r o l l i n g A l l e r g i c A s t h m a Several underlying diseases can present symptoms similar to asthma. Therefore, a correct diagnos
More informationManagement of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier
Management of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier Department of Pediatrics, Division of Allergy and Pulmonary Medicine, Washington
More informationExercise-Induced Bronchospasm. Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute
Exercise-Induced Bronchospasm Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute EIB Episodic bronchoconstriction with exercise May be an exacerbation
More informationLINEE GUIDA DELL ASMA: UP TO DATE
LINEE GUIDA DELL ASMA: UP TO DATE Azienda Ospedaliera Pisana Università degli Studi di Pisa Pierluigi Paggiaro GINA International Executive Committee, Chairman GINA ITaly Cardio-Thoracic and Vascular Department,
More informationEvolution of asthma from childhood. Carlos Nunes Center of Allergy and Immunology of Algarve, PT
Evolution of asthma from childhood Carlos Nunes Center of Allergy and Immunology of Algarve, PT allergy@mail.telepac.pt Questionnaire data Symptoms occurring once or several times at follow-up (wheeze,
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Measurement of Exhaled Nitric Oxide and Page 1 of 18 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate
More informationAsma e BPCO: le strategie terapeutiche
Asma e BPCO: le strategie terapeutiche Dott. Marco Contoli ctm@unife.it Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara COPD Definition Chronic Obstructive
More informationNIOX VERO. For assessment and management of airway inflammation
NIOX VERO For assessment and management of airway inflammation NIOX VERO NIOX VERO is a point-of-care device for assessing airway inflammation in patients with respiratory problems such as asthma. NIOX
More informationToday's presentation will focus on... A major health problem. Asthma. A new exciting Biomarker. Exhaled Nitric Oxide
Today's presentation will focus on... A major health problem Asthma A new exciting Biomarker Exhaled Nitric Oxide An attractive life science business Aerocrine AB Asthma is a major global health problem
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationUpdate on management of respiratory symptoms. Dr Farid Bazari Consultant Respiratory Physician Kingston Hospital NHS FT
Update on management of respiratory symptoms Dr Farid Bazari Consultant Respiratory Physician Kingston Hospital NHS FT Topics The common respiratory symptoms Cough: causes, diagnosis and therapy Update
More informationCurrent Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012
Subbasement Membrane Thickness(µm) 12/7/212 Current Asthma Therapy: Little Need to Phenotype Phenotypes of Severe Asthma Most mild and to some degree moderate asthmatics respond well to currently available
More informationBiologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
More informationCOPD and Asthma: Similarities and differences Prof. Peter Barnes
and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationMethacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges
Methacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges AAAAI San Antonio Tx February 2013 Catherine Lemière MD, MSc Hôpital du
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationPublic Dissemination
1. THE ASTHMA CONDITION 9 18 3 30 A. Pathophysiology 4 6 0 10 1. Teach an individual with asthma and their family using simple language by illustrating the following with appropriate educational aids a.
More informationCOPD or not COPD, that is the question.
COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationPediatric Asthma: Pharmacotherapy. Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado
Pediatric Asthma: Pharmacotherapy Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado Pediatric Asthma: Pharmacotherapy Disclosures/Conflicts of Interest:
More informationA primary care perspective on the new British asthma guideline
A primary care perspective on the new British asthma guideline Bronwen Thompson discusses the revisions to the BTS/SIGN guideline with Dr Hilary innock This guideline update 1 is significant. It builds
More informationASTHMA IN THE PEDIATRIC POPULATION
ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center
More informationAsthma: Classification, Management, Prevention and New Treatments
Asthma: Classification, Management, Prevention and New Treatments Cori Daines, MD, Professor Pediatric Pulmonary Medicine University of Arizona April 28, 2018 I have no relevant financial relationships
More informationProf Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital
Prof Neil Barnes Respiratory and General Medicine London Chest Hospital and The Royal London Hospital ASTHMA: WHEN EVERYTHING FAILS WHAT DO YOU DO? South GP CME 2013, Dunedin Saturday 17 th August 2013
More informationAsthma and Vocal Cord Dysfunction
Asthma and Vocal Cord Dysfunction Amy L. Marks DO, FACOP Pediatric Allergy and Immunology Assistant Professor of Pediatrics Oakland University William Beaumont School of Medicine Objectives: Understanding
More informationEndobronchial Thermoplasty
Endobronchial Thermoplasty Asthma Education Day Thursday, October 30, 2014 Cynthia Ray, MD, FCCP Senior Staff Physician Interventional Pulmonology Pulmonary and Critical Care Medicine Henry Ford Hospital
More informationEFFECTIVE ASTHMA MANAGEMENT IN PRIMARY CARE Severity Assessment, Guidelines, and New Therapeutic Options
Educational Objectives EFFECTIVE ASTHMA MANAGEMENT IN PRIMARY CARE Bradley E. Chipps, MD, FAAP, FACAAI, FAAAAI, FCCP President-Elect, American College of Allergy, Asthma & Immunology Medical Director,
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationBronchial asthma. E. Cserháti 1 st Department of Paediatrics. Lecture for english speaking students 5 February 2013
Bronchial asthma E. Cserháti 1 st Department of Paediatrics Lecture for english speaking students 5 February 2013 Epidemiology of childhood bronchial asthma Worldwide prevalence of 7-8 and 13-14 years
More informationAir Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.
Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,
More informationClinical Policy Bulletin: Exhaled Breath Tests
Clinical Policy Bulletin: Exhaled Breath Tests Number: 0691 Policy *Pleasesee amendment forpennsylvaniamedicaidattheendofthiscpb. Aetna considers hydrogen breath testing (HBT) medically necessary for evaluation
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationAsthma: diagnosis and monitoring
Asthma: diagnosis and monitoring NICE guideline: short version Draft for second consultation, July 01 This guideline covers assessing, diagnosing and monitoring suspected or confirmed asthma in adults,
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationAsthma Update I have no professional or personal financial conflicts of interest to disclose.
Asthma Update 2018 Disclosures Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical Center I have
More informationAsthma Update Jennifer W. McCallister, MD, FACP, FCCP
Asthma Update 2018 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical Center Disclosures I have
More informationAsthma in Pregnancy. Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA. Introduction
Asthma in Pregnancy Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA Introduction Asthma is the most common potentially serious medical problem to complicate
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More information